South Africa Central Nervous System (CNS) Therapeutic Market : Table of Contents

1. Introduction

1.1 Report Guidance

1.2 Market Segmentation

2. Executive Summary

2.1 Key Market Insights

2.2 Market Attractiveness

3. Research Methodology

3.1 Secondary Research

3.2 Primary Research

3.2.1 Data Triangulation and Validation

4. South Africa Central Nervous System (CNS) Therapeutic Market Landscape

4.1 Overview

4.3 Ecosystem Analysis

4.3.1 List of Vendors in the Value Chain

5. South Africa Central Nervous System (CNS) Therapeutic Market – Key Market Dynamics

5.1 Market Drivers

5.2 Market Restraints

5.3 Market Opportunities

5.4 Future Trends

5.5 Impact of Drivers and Restraints

6. South Africa Central Nervous System (CNS) Therapeutic Market Country Analysis

6.2 South Africa Central Nervous System (CNS) Therapeutic Market Revenue 2016-2027 (US$ Million)

6.3 South Africa Central Nervous System (CNS) Therapeutic Market Forecast Analysis

7. South Africa Central Nervous System (CNS) Therapeutic Market Analysis – by Disease Type

7.1 Neurovascular Diseases

7.1.1 Overview
7.1.2 Neurovascular Diseases: South Africa Central Nervous System (CNS) Therapeutic Market – Revenue and Forecast, 2016-2027 (US$ Million)

7.2 Degenerative Disorders

7.2.1 Overview
7.2.2 Degenerative Disorders: South Africa Central Nervous System (CNS) Therapeutic Market – Revenue and Forecast, 2016-2027 (US$ Million)

7.3 Mental Health

7.3.1 Overview
7.3.2 Mental Health: South Africa Central Nervous System (CNS) Therapeutic Market – Revenue and Forecast, 2016-2027 (US$ Million)

7.4 Trauma

7.4.1 Overview
7.4.2 Trauma: South Africa Central Nervous System (CNS) Therapeutic Market – Revenue and Forecast, 2016-2027 (US$ Million)

8. South Africa Central Nervous System (CNS) Therapeutic Market Analysis – by Drug Type

8.1 Analgesics

8.1.1 Overview
8.1.2 Analgesics: South Africa Central Nervous System (CNS) Therapeutic Market – Revenue and Forecast, 2016-2027 (US$ Million)

8.2 Nervous System Drugs

8.2.1 Overview
8.2.2 Nervous System Drugs: South Africa Central Nervous System (CNS) Therapeutic Market – Revenue and Forecast, 2016-2027 (US$ Million)

8.3 Anesthetics

8.3.1 Overview
8.3.2 Anesthetics: South Africa Central Nervous System (CNS) Therapeutic Market – Revenue and Forecast, 2016-2027 (US$ Million)

8.4 Anti-Parkinson Drugs

8.4.1 Overview
8.4.2 Anti-Parkinson Drugs: South Africa Central Nervous System (CNS) Therapeutic Market – Revenue and Forecast, 2016-2027 (US$ Million)

8.5 Anti-Epileptics

8.5.1 Overview
8.5.2 Anti-Epileptics: South Africa Central Nervous System (CNS) Therapeutic Market – Revenue and Forecast, 2016-2027 (US$ Million)

9. South Africa Central Nervous System (CNS) Therapeutic Market Analysis – by Distribution Channel

9.1 Hospital Pharmacies

9.1.1 Overview
9.1.2 Hospital Pharmacies: South Africa Central Nervous System (CNS) Therapeutic Market – Revenue and Forecast, 2016-2027 (US$ Million)

9.2 Retail Pharmacies

9.2.1 Overview
9.2.2 Retail Pharmacies: South Africa Central Nervous System (CNS) Therapeutic Market – Revenue and Forecast, 2016-2027 (US$ Million)

10. South Africa Central Nervous System (CNS) Therapeutic Market – South Africa Analysis

10.1 South Africa

10.1.1 South Africa: South Africa Central Nervous System (CNS) Therapeutic Market – Revenue and Forecast to 2027 (US$ Million)

10.1.1.1 South Africa: South Africa Central Nervous System (CNS) Therapeutic Market Breakdown, by Disease Type
10.1.1.2 South Africa: South Africa Central Nervous System (CNS) Therapeutic Market Breakdown, by Drug Type
10.1.1.3 South Africa: South Africa Central Nervous System (CNS) Therapeutic Market Breakdown, by Distribution Channel

11. Competitive Landscape

11.1 Heat Map Analysis

11.2 Company Positioning and Concentration

12. Industry Landscape

12.1 Overview

12.2 Market Initiative

12.3 Partnerships and Collaborations

12.4 Other Developments

13. Company Profiles

13.1 Eli Lilly and company

13.1.1 Key Facts
13.1.2 Business Description
13.1.3 Products and Services
13.1.4 Financial Overview
13.1.5 SWOT Analysis
13.1.6 Key Developments

13.2 Pfizer Inc.

13.2.1 Key Facts
13.2.2 Business Description
13.2.3 Products and Services
13.2.4 Financial Overview
13.2.5 SWOT Analysis
13.2.6 Key Developments

13.3 Merck & Co., Inc.

13.3.1 Key Facts
13.3.2 Business Description
13.3.3 Products and Services
13.3.4 Financial Overview
13.3.5 SWOT Analysis
13.3.6 Key Developments

13.4 AstraZeneca

13.4.1 Key Facts
13.4.2 Business Description
13.4.3 Products and Services
13.4.4 Financial Overview
13.4.5 SWOT Analysis
13.4.6 Key Developments

13.5 Novartis AG

13.5.1 Key Facts
13.5.2 Business Description
13.5.3 Products and Services
13.5.4 Financial Overview
13.5.5 SWOT Analysis
13.5.6 Key Developments

13.6 Takeda Pharmaceutical Company Limited

13.6.1 Key Facts
13.6.2 Business Description
13.6.3 Products and Services
13.6.4 Financial Overview
13.6.5 SWOT Analysis
13.6.6 Key Developments

13.7 Teva Pharmaceutical Industries Ltd.

13.7.1 Key Facts
13.7.2 Business Description
13.7.3 Products and Services
13.7.4 Financial Overview
13.7.5 SWOT Analysis
13.7.6 Key Developments

13.8 Lundbeck

13.8.1 Key Facts
13.8.2 Business Description
13.8.3 Products and Services
13.8.4 Financial Overview
13.8.5 SWOT Analysis
13.8.6 Key Developments

13.9 Adcock Ingram

13.9.1 Key Facts
13.9.2 Business Description
13.9.3 Products and Services
13.9.4 Financial Overview
13.9.5 SWOT Analysis
13.9.6 Key Developments

13.10 Lupin Limited

13.10.1 Key Facts
13.10.2 Business Description
13.10.3 Products and Services
13.10.4 Financial Overview
13.10.5 SWOT Analysis
13.10.6 Key Developments

14. Appendix

14.1 About Business Market Insights

14.2 List of Abbreviations

South Africa Central Nervous System (CNS) Therapeutic Market